A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers

LESSONS LEARNED. OPB‐111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation that exhibited promising anticancer activity in preclinical models. In this first‐in‐human phase I study of OPB‐111077 in unselected advanced cancers, treatment‐emergent adverse events, most frequen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Tolcher, Anthony, Flaherty, Keith, Shapiro, Geoffrey I., Berlin, Jordan, Witzig, Thomas, Habermann, Thomas, Bullock, Andrea, Rock, Edwin, Elekes, Agnes, Lin, Chester, Kostic, Dusan, Ohi, Naoto, Rasco, Drew, Papadopoulos, Kyriakos P., Patnaik, Amita, Smith, Lon, Cote, Gregory M.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6067949/
https://ncbi.nlm.nih.gov/pubmed/29511132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0325
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados